Evotec Investor Presentation Deck

PAGE 32 evotec Setting the pace to accelerate growth along Action Plan 2025 Selected major newsflow 2022 R&D efficiency platforms Precision medicine platforms Just - Evotec Biologics Group & ESG ● ● ● ● ● ● ● Undisrupted growth of base business, in-line with AP 2025 (EVOIR&D) New integrated drug discovery & development alliances Significant capacity and value chain expansion for all modalities New strategic partnerships and expansions of co-owned alliances New clinical trial initiations Significant progress of later stage co-owned pipeline (EVOroyalty) Spin-Offs and investments along Building Blocks of AP 2025 (EVO equity) Start of production J.POD® Redmond, WA (US) Start of construction J.POD® Toulouse, France (EU) Evaluation of global network of J.PODSⓇ (EVO access) Undisrupted growth trend versus 2021 in line with AP 2025 Growth of unpartnered R&D investments faster than top-line Validated science-based targets aligned with 1.5°C goal Highly impactful contribution to UN SDG 3¹) ¹)UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on women's health, fight against infectious diseases and pandemic preparedness

View entire presentation